RxDoctor Payments Data

Kyle Kessler, APRN

Psychiatric/Mental Health · Cleburne, TXNPI 1649934985

Payments from drug & device makers

$9,097in general payments, 2019–2025

Across 602 payments — averaging $15.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Alkermes, Inc.$1K
  • AbbVie$1K
  • Neurocrine Biosciences, Inc.$761
  • Otsuka America Pharmaceutical, Inc.$670
  • plus $2K from 8 others

What the payments were for

  • Food & beverage$8,97499%
  • Education$1231%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,097 in reported general payments places this provider in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$4,320
Medicare patients
18
Services billed
58

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl53$78,062
AristadaAripiprazole Lauroxil13$41,458
LybalviOlanzapine/Samidorphan Malate12$20,915
Aripiprazole67$3,913
Quetiapine Fumarate103$1,801
Clozapine12$1,678
Buspirone Hcl73$1,393
Olanzapine52$1,318
Hydroxyzine Pamoate66$958
Divalproex Sodium23$929
Duloxetine Hcl21$901
Lamotrigine86$900
Bupropion XlBupropion Hcl48$890
Oxcarbazepine16$878
Gabapentin42$860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,214$78,06253 claims
Alkermes, Inc.Aristada, Lybalvi$1,309$62,37325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Cleburne

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →